To access the conference call, please dial (855) 437-4406 (local) or (484) 756-4292 (international) at least five minutes prior to the start time and refer to conference ID 41661952. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the company's website, investors.karyopharm.com/events.cfm. An archived webcast will be available on the company's website approximately two hours after the event.
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). SINE™ compounds have also shown biological activity in models of cancer, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in
Justin Renz(617) 658-0574 email@example.com Gina Nugent(617) 460-3579 firstname.lastname@example.org
Source: Karyopharm Therapeutics
News Provided by Acquire Media